DESCRIPTION: (from Abstract) Most studies dealing with monoamine
oxidase (MAO) have emphasized the development of inhibitors of
this enzyme for controlling neurotransmitter metabolism in patients
with diseases such as Parkinson's. The literature is replete with
information on natural and man-made inhibitors of MAO activity.
However, there is virtually no information on modulators of MAO that
result in enhanced activity of this enzyme. The applicants' laboratory
has recently demonstrated that diadenosine tetraphosphate, Ap4A, may be
one, of only a few, endogenous extracellular stimulatory agents of
MAO activity. They have undertaken a series of experiments aimed
at understanding the signal transduction pathway associated with Ap4A
receptor binding and the enhanced activation of MAO. An understanding
of the transduction pathway(s) involved with Ap4A receptor activation may
result in a better understanding of the signal transduction events
associated with MAO activation. In addition, if the Ap4A activated
transduction pathway(s) is a novel activation pathway(s) for MAO,
knowledge of this pathway(s) may allow for the development of a new
class of agonists, antagonists or pharmacological agents for
controlling MAO activity. Abnormal or elevated level of Ap4A in the
CNS and adrenal gland may lead to pathogenic conditions associated
with depleted catecholamine stores, such as Parkinson's Disease. The
potential importance of MAO in the catabolism of various
xenobiotics suggests that Ap4A may have an important therapeutic role.
The specific aims of this proposal are: (A) To determine the dosage
effects of the extracellular diadenosine polyphosphates on MAO activity
in PC12 cells and brain synaptosomes obtained form the caudate putamen
of rat brains. Dopamine metabolites will be measured by using 1) HPLC
with electrochemical detection and 2) radiochemical analyses. The
temporal dynamics of the application of Ap4A will be determined to
assess the effects of short term and chronic exposure of the cells
and synaptosomes; (B) To determine the effects of extracellular
Ap4A on adenylate cyclase activity and cAMP levels in PC12 cells.
cAMP levels will be assayed by an enzyme linked immunoassay; adenylate
cyclase activity will be determined using [a32P] ATP and chromatography;
(C) To determine the role of G protein involvement in the Ap4A
elicited response by measuring GTPase enzymatic activity; (D) To
determine the involvement of tyrosine kinases and tyrosine
phosphatases in the Ap4A initiated signal transduction pathway.
SDS-PAGE and [32P]phosphate will be used to label cells and determine
the extent of phosphorylation or dephosphorylation of specific
proteins. (E) To determine the effects of Ap4A delivery to the
caudate putamen of the conscious rat with in vivo microdialysis in
conjunction with HPLC.
National Institute of Neurological Disorders and Stroke
CFDA Code
DUNS Number
042629816
UEI
H2BMNX7DSKU8
DVDTEN65ZVA5
ZANHDZK2QZF4
Project Start Date
01-May-1996
Project End Date
30-April-1999
Budget Start Date
01-May-1996
Budget End Date
30-April-1999
Project Funding Information for 1996
Total Funding
$109,500
Direct Costs
$75,000
Indirect Costs
$34,500
Year
Funding IC
FY Total Cost by IC
1996
NIH Office of the Director
$109,500
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R15NS035294-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R15NS035294-01
Patents
No Patents information available for 1R15NS035294-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R15NS035294-01
Clinical Studies
No Clinical Studies information available for 1R15NS035294-01
News and More
Related News Releases
No news release information available for 1R15NS035294-01
History
No Historical information available for 1R15NS035294-01
Similar Projects
No Similar Projects information available for 1R15NS035294-01